<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03756649</url>
  </required_header>
  <id_info>
    <org_study_id>18-007941</org_study_id>
    <nct_id>NCT03756649</nct_id>
  </id_info>
  <brief_title>Mayo Clinic IBD Biobank</brief_title>
  <official_title>Mayo Clinic IBD Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are collecting and storing blood, stool, and urine samples and medical
      information to better understand Inflammatory Bowel Disease (IBD) to improve disease outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be sent a letter detailing the proposed biobank and soliciting enrollment.
      Following the informed consent process, subjects will provide a blood sample (50 ml), urine
      sample (50 ml), and stool. The blood and urine samples will either be collected at the one of
      the Mayo Clinic outpatient laboratories or by a mail-out kit. Subjects will be asked to
      complete a questionnaire and 24-hour food recall questionnaire (completed online).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 2065</completion_date>
  <primary_completion_date type="Anticipated">December 2065</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Participants</measure>
    <time_frame>50 years</time_frame>
    <description>Total number of participants in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Collection</measure>
    <time_frame>50 years</time_frame>
    <description>Total number of urine samples collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Collection</measure>
    <time_frame>50 years</time_frame>
    <description>Total number of blood samples collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Collection</measure>
    <time_frame>50 years</time_frame>
    <description>Total number of stool samples collected</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inflammatory bowel disease (IBD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>50 ml will be collected</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Inflammatory bowel disease (IBD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urine Collection</intervention_name>
    <description>50 ml will be collected</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Inflammatory bowel disease (IBD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stool Collection</intervention_name>
    <description>Three 25 ml tubes will be collected</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Inflammatory bowel disease (IBD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with inflammatory bowel disease (IBD) who are between the ages of
             18 and 85 at time of study enrollment.

          -  The diagnosis of IBD will be based on the standard IBD criteria including biochemical
             and colonoscopy screening.

          -  Women with inflammatory bowel disease of childbearing potential and pregnant women
             will be offered enrollment because there is no risk to an unborn child in this
             investigation.

          -  Patients between the ages of 18 and 85 without history of IBD or colon cancer.

        Exclusion Criteria:

          -  Patients with known liver disease.

          -  Patients unable to provide informed consent.

          -  Prisoners and institutionalized individuals.

          -  Patients with a history of colorectal cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos N. Lazaridis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Konstantinos N. Lazaridis, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>Crohn's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

